TABLE 39, Sensitivity analyses - What is the Clinical Effectiveness and Cost-Effectiveness of Using Drugs in Treating Obese Patients in Primary Care? A Systematic Review

Warning: The NCBI web site requires JavaScript to function. more...

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Ara R, Blake L, Gray L, et al. What is the Clinical Effectiveness and Cost-Effectiveness of Using Drugs in Treating Obese Patients in Primary Care? A Systematic Review. Southampton (UK): NIHR Journals Library; 2012 Feb. (Health Technology Assessment, No. 16.5.)

Cover of What is the Clinical Effectiveness and Cost-Effectiveness of Using Drugs in Treating Obese Patients in Primary Care? A Systematic Review

What is the Clinical Effectiveness and Cost-Effectiveness of Using Drugs in Treating Obese Patients in Primary Care? A Systematic Review.

Show details

Contents

TABLE 39Sensitivity analyses

Sensitivity analysis	Base case	Variable		Life-years	Cost(£)	Discounted cost(£)	QALYs	Discounted QALYs	Incremental cost (£)	Incremental QALYs	ICER (£)
Base case			Placebo	75.495	5286	2806	25.12	15.13
Base case			Orlistat	75.758	5547	3097	25.47	15.30	291	0.1750	1665
SA1	Weight regain period 36 months	Weight regain period 12 months	Placebo	75.163	5373	2942	24.86	14.99
SA1	Weight regain period 36 months	Weight regain period 12 months	Orlistat	75.440	5606	3211	25.14	15.10	269	0.1130	2379
SA2	BMI regain to baseline BMI	BMI regain to trajectory of natural history	Placebo	74.880	6090	3209	22.72	13.82
SA2	BMI regain to baseline BMI	BMI regain to trajectory of natural history	Orlistat	75.115	6406	3530	22.95	13.91	321	0.0927	3466
SA3	Treatment duration 12 months	Treatment duration 24 months	Placebo	75.454	5342	2846	25.09	15.12
SA3	Treatment duration 12 months	Treatment duration 24 months	Orlistat	75.714	5562	3115	25.35	15.21	270	0.0951	2835
SA4	Starting age 45.5 years	Starting age 20 years	Placebo	67.860	10,266	4130	41.74	20.10
SA4	Starting age 45.5 years	Starting age 20 years	Orlistat	68.056	10,421	4396	41.95	20.15	266	0.0508	5240
SA4	Starting age 45.5 years	Starting age 60 years	Placebo	79.557	3748	2441	15.89	10.98
SA4	Starting age 45.5 years	Starting age 60 years	Orlistat	79.733	4082	2775	16.05	11.07	334	0.0878	3798
SA5	Base case uses a distribution of 74.3% women and 25.7% men	All female	Placebo	73.960	6564	3564	23.77	14.47
SA5	Base case uses a distribution of 74.3% women and 25.7% men	All female	Orlistat	74.382	6871	3865	24.11	14.60	301	0.1336	2257
SA6	Baseline BMI 34.92 kg/m²	Baseline BMI 30 kg/m²	Placebo	79.339	1085	524	29.62	17.11
SA6	Baseline BMI 34.92 kg/m²	Baseline BMI 30 kg/m²	Orlistat	79.343	1436	887	29.65	17.13	363	0.0153	23,720
SA6	Baseline BMI 34.92 kg/m²	Baseline BMI 40 kg/m²	Placebo	74.257	6105	3300	23.73	14.54
SA6	Baseline BMI 34.92 kg/m²	Baseline BMI 40 kg/m²	Orlistat	74.440	6368	3599	23.85	14.59	299	0.0485	6155

From: Appendix 5, De novo cost-effectiveness model

Included under terms of UK Non-commercial Government License.

Contents

Views

Cite this Page
Ara R, Blake L, Gray L, et al. What is the Clinical Effectiveness and Cost-Effectiveness of Using Drugs in Treating Obese Patients in Primary Care? A Systematic Review. Southampton (UK): NIHR Journals Library; 2012 Feb. (Health Technology Assessment, No. 16.5.) TABLE 39, Sensitivity analyses.
PDF version of this title (17M)

Other titles in this collection

Health Technology Assessment

Recent Activity

Clear Turn Off Turn On

TABLE 39, Sensitivity analyses - What is the Clinical Effectiveness and Cost-Eff...
TABLE 39, Sensitivity analyses - What is the Clinical Effectiveness and Cost-Effectiveness of Using Drugs in Treating Obese Patients in Primary Care? A Systematic Review

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on